Pages that link to "Q34273722"
Jump to navigation
Jump to search
The following pages link to Bisphosphonates for osteoporosis--where do we go from here? (Q34273722):
Displaying 50 items.
- Applying evidence-based medicine principles to hip fracture management (Q24273316) (← links)
- Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea (Q26771713) (← links)
- Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research (Q26782621) (← links)
- Osteoporosis Treatment: When to Discontinue and When to Re-start (Q26858980) (← links)
- Prevention and treatment of bone changes associated with exposure to glucocorticoids (Q26861474) (← links)
- Consequences of irradiation on bone and marrow phenotypes, and its relation to disruption of hematopoietic precursors (Q26864483) (← links)
- Bisphosphonate drug holiday: choosing appropriate candidates (Q27004682) (← links)
- Epidemiology and management of osteoporosis in the People's Republic of China: current perspectives (Q27005978) (← links)
- Rib fractures and death from deletion of osteoblast βcatenin in adult mice is rescued by corticosteroids (Q27316361) (← links)
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial (Q30978614) (← links)
- Observations following discontinuation of long-term denosumab therapy. (Q33563846) (← links)
- Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy (Q33568586) (← links)
- A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring (Q33570209) (← links)
- Trajectories of Bone Remodeling Markers and Bone Mineral Density during Treatment with Strontium Ranelate in Postmenopausal Women Previously Treated with Bisphosphonates (Q33572835) (← links)
- Rethinking the Appraisal and Approval of Drugs for Fracture Prevention (Q33679213) (← links)
- Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays (Q33715141) (← links)
- Patient perceptions of osteoporosis treatment thresholds (Q33766971) (← links)
- Quality of osteoporosis care of older Medicare recipients with fragility fractures: 2006 to 2010. (Q33854982) (← links)
- Effect of self-referral on bone mineral density testing and osteoporosis treatment (Q33911512) (← links)
- Time and dose-dependent effects of Labisia pumila on bone oxidative status of postmenopausal osteoporosis rat model (Q34091807) (← links)
- Increase in the serum parathyroid hormone level during a bisphosphonate drug holiday (Q34219208) (← links)
- Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial (Q34375420) (← links)
- Breast cancer survivorship issues (Q34895561) (← links)
- Risk of atypical femoral fracture during and after bisphosphonate use. (Q35197628) (← links)
- Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study (Q35536507) (← links)
- Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study. (Q35597843) (← links)
- Effects of OsteoKing on osteoporotic rabbits (Q35628178) (← links)
- Non-Ototoxic Local Delivery of Bisphosphonate to the Mammalian Cochlea (Q35748623) (← links)
- Chronic kidney disease and the skeleton (Q35755179) (← links)
- Preservation and promotion of bone formation in the mandible as a response to a novel calcium-phosphate based biomaterial in mineral deficiency induced low bone mass male versus female rats (Q35935718) (← links)
- The effect of sequential therapy for postmenopausal women with osteoporosis: A PRISMA-compliant meta-analysis of randomized controlled trials. (Q36215878) (← links)
- The Prevention of Medication-related Osteonecrosis of the Jaw. (Q36292333) (← links)
- Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years (Q36309349) (← links)
- Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data (Q36378748) (← links)
- Eleven years of experience with bisphosphonate plus alfacalcidol treatment in a man with osteogenesis imperfecta type I (Q36500182) (← links)
- Oral bisphosphonates may not decrease hip fracture risk in elderly Spanish women: a nested case-control study (Q36649749) (← links)
- Implant-delivered Alendronate Causes a Dose-dependent Response on Net Bone Formation Around Porous Titanium Implants in Canines (Q36746791) (← links)
- Prevalence of Fracture Risk Factors in Postmenopausal Women Enrolled in the POSSIBLE US Treatment Cohort (Q36766167) (← links)
- Osteoporosis - a current view of pharmacological prevention and treatment (Q36939677) (← links)
- Bisphosphonate drug holiday: who, when and how long (Q36999714) (← links)
- Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis (Q37018032) (← links)
- Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. (Q37135281) (← links)
- Effects of salvianolate on bone metabolism in glucocorticoid-treated lupus-prone B6.MRL-Fas (lpr) /J mice (Q37175331) (← links)
- Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative (Q37237785) (← links)
- Effects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk-hydroxyapatite films (Q37392009) (← links)
- Use of combination therapy in the treatment of primary osteoporosis: protocol for a network meta-analysis of randomised trials (Q37454589) (← links)
- Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model (Q37476433) (← links)
- Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties. (Q37682081) (← links)
- Bisphosphonates and atypical subtrochanteric fractures of the femur. (Q37733851) (← links)
- Bisphosphonates and their clinical implications in endodontic therapy. (Q38058563) (← links)